Guard Therapeutics presents top-line results of Phase 2 (AKITA) study, 2023

September 19th 2023 14:00 (Europe/Stockholm)

Language:

English

Speaker:

Tobias Agervald, CEO and Michael Reusch, CMO

Sector:

Health care - Pharmaceuticals & Biotechnology

Listing:

First North

Activity:

Audiocast with teleconference

Webcast:

https://ir.financialhearings.com/update-sep-2023

Teleconference:

Dial-in number to the teleconference will be received by registering on the link below. After the registration you will be provided phone numbers and a conference/user ID to access the conference.
https://conference.financialhearings.com/teleconference/?id=5003122